Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

NCT04782895 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

488

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer
Condylomata Acuminata

Interventions

BIOLOGICAL: Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
BIOLOGICAL: Gardasil®9

Sponsor

Xiamen University

Collaborators

[object Object]
[object Object]